AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06216145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: formative evaluation
Description: Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method
Study NCT06216145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: formative evaluation
Description: Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method
Study NCT06024057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX101
Description: LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
Study NCT05847231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceived Stress, Mandala application
Description: Mandala
Study NCT04818281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine
Description: VLP adjuvanted vaccine
Study NCT04818281 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study NCT04701645 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microdevice
Description: Placement of 1 to 6 implantable microdevices with multiple miniature drug reservoirs into a tumor mass 24 +/- 8 hours prior to surgery. Drugs will be released over 24 (+/- 8) hours while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice will harbor up to 20 drugs and drug combinations relevant to the treatment of ovarian cancer.~* Each drug or drug combination will be released from a single, separate reservoir. At least two reservoirs will harbor a drug vehicle only.~* Drugs will include all or a subset of the following: Cisplatin, Carboplatin, Paclitaxel, Doxorubicin or pegylated liposomal doxorubicin (PLD), Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide, Pemetrexed, Topotecan, Vinorelbine, Olaparib, Niraparib, Rucaparib, Carboplatin + paclitaxel (combination), Carboplatin + doxorubicin (combination),Carboplatin + gemcitabine (combination)
Study NCT05947370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Chloride
Description: Traditional Chinese medicine
Study NCT05947370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Berberine Chloride
Description: Traditional Chinese medicine
Study NCT05947370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control
Study NCT05947370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT05670366 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Activity tracker and chest strap
Description: During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).
Study NCT05670366 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diary app
Description: During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.
Study NCT04644744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
Study NCT04644744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
Study NCT04644744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermic machine perfusion (NMP)
Description: End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
Study NCT06633770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: proclcitonin and presepsin
Description: All included patients will be subjected to:~* laboratory investigations~  * Complete Blood Count (CBC),~ * Liver Function Test(LFT) ( ALT,AST, Billirubin, total protein and albumin)~ * Kidney function test (KFT) ( Urea and creatinine)~ * Random Blood Glucose (RBG).~ * Erythrocyte Sedimentation Rate(ESR )~ * Urine analysis -A special investigations include (blood culture, C Reactive protein (CRP), proclcitonin and presepsin).
Study NCT06173271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi-intervention program and protein foods supplementation
Description: This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
Study NCT06173271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: multi-intervention program and protein foods supplementation
Description: This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
Study NCT06233773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio Taping
Study NCT06233773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymph Drainage
Description: Manual Lymph Drainage Group
Study NCT06233773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control Group
Study NCT06113302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Given by SC or (Injection)
Study NCT06206629 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blink reflex evaluation
Description: A blink reflex evaluation will be performed in all subjects
Study NCT04644744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Description: End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
Study NCT05145855 — intervention group
Intervention type: OTHER
Intervention: Patient-tailored multimodal neglect rehabilitation
Description: Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
Study NCT04947631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-313
Description: Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
Study NCT04947631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: Dutasteride 0.5 mg once daily for 48 weeks
Study NCT04947631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 5 mg once daily for 48 weeks
Study NCT04947631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DKF-313 placebo
Description: Once daily for 48 weeks
Study NCT04947631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride placebo
Description: Once daily for 48 weeks
Study NCT04947631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride placebo
Description: Once daily for 48 weeks
Study NCT04947631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil placebo
Description: Once daily for 48 weeks
Study NCT04947631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil placebo
Description: Once daily for 48 weeks
Study NCT04859244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: 750 mg administered as a solution
Study NCT05744726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: 0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
Study NCT05744726 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bone-wax
Description: 0.5 to 1g of Bone-wax for each dental socket
Study NCT06348615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-cellulite cream-gel Medical Device (DEFBODY)
Description: one bottle of 400 ml, twice a day
Study NCT05335564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General information about depression
Description: Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression.
Study NCT05618041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Autologous T cell injection
Description: Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis
Study NCT05851781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide tablet
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT05851781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT05398601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MOBILIZATION with MOVEMENT
Description: They would be receiving conventional treatment as follow:~TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive MWM techniques for Knee~1. Medial glide~2. Medial+ Internal rotation glide~3. Lateral Glide+ Internal Rotation glide~4. Anterior glide~5. Posterior glide
Study NCT05398601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periosteal electrical dry needling
Description: They would be receiving conventional treatment as follow:~TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee~Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone:~1. Medial femoral condyle~2. Lateral femoral condyle~3. Flare of the tibia~4. Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST.
Study NCT05040841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result
Description: Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the Risk of Treatment Failure (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1.
Study NCT05607498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB07
Description: EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
Study NCT05630222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: Ibuprofen from Caspian Taamin Company
Study NCT05630222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate from Darupakhsh Company
Study NCT05630222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg plus Acetaminophen 1000 mg
Description: Both from Caspian Taamin Company
Study NCT05040841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M2/PRM: Immediate outreach to subject after a missed pharmacy refill
Description: The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
Study NCT05040841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M3/EAM: Immediate outreach to subject after EAM-identified missed doses
Description: The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
Study NCT06581055 — intervention group
Intervention type: DRUG
Intervention: Luspatercept
Description: As per COMMANDS Trial (NCT03682536) study protocol
Study NCT06581055 — intervention group
Intervention type: DRUG
Intervention: Epoetin Alfa
Description: As per COMMANDS Trial (NCT03682536) study protocol
Study NCT05040841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S1/Text: Weekly check-in texts
Description: Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent.
Study NCT06041789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg tablet
Study NCT06041789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Donepezil placebo tablet
Study NCT06259305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creation of a memory track combined with the baby's heartbeat
Description: This is as described above
Study NCT05908409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-121
Description: IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
Study NCT05281536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ppostural change from 45° to 10° in supine position
Description: The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
Study NCT06508645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP14012 injection
Description: 1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)
Study NCT06508645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 injection
Description: 1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)
Study NCT05298995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CART01 (iC9-GD2-CAR T-cells)
Description: Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
Study NCT04829305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285
Description: SHR2285 is a selective inhibition of human FXIa small molecule compound.
Study NCT06301867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plateau Pressure
Description: Plateau pressure will be measured on all patients in the participating intensive care units prior to extubation.
Study NCT04813224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAUMA CENTERED EMDR-BASED TREATMENT and TRAUMA-FOCUSED CBT-BASED TREATMENT
Description: Psychological evidence-based intervention for the reduction of the impact of childhood sexual abuse.
Study NCT05273216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Duplex Sonography
Description: Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.